scholarly journals Effect of age on procoagulants in people with obesity at Sapele, Southern Nigeria

2021 ◽  
Vol 11 (2) ◽  
pp. 058-063
Author(s):  
Kingsley Chukwuka Amaihunwa ◽  
Emmanuel Asuquo Etim ◽  
Everista Odaburhine Osime ◽  
Zacchaeus Awortu Jeremiah
Keyword(s):  
Plasminogen Activator ◽  
Venous Blood ◽  
Plasminogen Activator Inhibitor ◽  
Obese People ◽  
Aged People ◽  
Southern Nigeria ◽  
Age Range ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Effect Of Age

Background/Objectives: Aged people with obesity are vulnerable to coagulation disorders arising from alterations in procaogulants. Therefore, this study aims to evaluate the effect of age on procaogulant such as: fibrinogen (FG), von willebrand factor (vWF), Soluble Vascular Cell Adhesion Molecules (sVCAM) tissue factor (TF), Tissue Plasminogen Activator (tPA) and Plasminogen Activator Inhibitor (PAI) in obese people. Materials and Method: 312 subjects with age between 18 and 65years were enrolled for this study comprising of 111males and 201females who were further grouped into age ranges of 20-39years, 40-49years and 50-59years respectively. 4.5mls of venous blood was collected into Ethylene Diamine Tetra-acetic Acid (EDTA) container. Plasma obtained was analyzed using ELISA method. Results: FG values in obese people within age range 20-29years was 100.59±209.23ng/ml while FG level of people within age range 40-49years and 50-59years were71.14±64.24ng/ml and 41.83±15.63ng/ml respectively at p<0.05. PAI of those within age range of 20-39years was 411.65±349.88pg/ml while PAI of people in age range of 50-59years was 265.92±64.30pg/ml. sVCAM of people in the age range of 20-39years was 8.24±12.61u/l and people within the age range of 50-59years had sVCAM value of 4.42±1.17u/l. TF values of people within the age range of 20-39years was 82.03±54.21pg/ml while people in the age range of 50-59years had TF value of 74.54±20.05pg/ml at P<0.05. vWF of people within age range of 50-59years was 84.88±58.96u/l while younger people in the age range of 20-29years had vWF value of 74.59±55.32u/l at P<0.05. Conclusion: Procaogulants such as: FG, PAI, sVCAM and TF were higher in younger people than in older people with obesity at Sapele southern Nigeria.

scholarly journals Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease

2011 ◽  
Vol 17 (6) ◽  
pp. 600-604 ◽  
Author(s):  
Huseyin Alkim ◽  
Selime Ayaz ◽  
Canan Alkim ◽  
Aysel Ulker ◽  
Burhan Sahin
Keyword(s):  
Plasminogen Activator ◽  
Degradation Products ◽  
Plasminogen Activator Inhibitor ◽  
Protein S ◽  
Plasminogen Activator Inhibitor 1 ◽  
Inflammatory Bowel ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor ◽  
D Dimer

This study was planned for searching possible changes of the total coagulation and fibrinolysis system in inflammatory bowel disease (IBD) in order to obtain some clues for explaining the relation between IBD and hypercoagulability. A total of 24 patients with ulcerative colitis, 12 patients with Crohn disease, and 20 healthy controls were studied. Platelets; prothrombin time (PT); partial thromboplastin time (PTT); fibrinogen; d-dimer; fibrinogen degradation products; protein C; protein S; antithrombin; thrombin time; von Willebrand factor; coagulation factors V, VII, VIII, IX, XI, and XIII; plasminogen; antiplasmin; tissue plasminogen activator; plasminogen activator inhibitor 1; and prothrombin fragments 1 + 2 were studied. Most of the procoagulants (platelets, fibrinogen, von Willebrand factor, coagulation factor IX, and plasminogen activator inhibitor 1) were found increased together with decreases in some anticoagulants (protein S and antithrombin) in IBD. Also the activation markers of coagulation (d-dimer, fibrinogen degradation products, and prothrombin fragments 1 + 2) were all increased. The parameters of the total coagulation–fibrinolysis system were increased in IBD, regardless of the form and the activity of the disease.

Von Willebrand Factor, Plasminogen Activator Inhibitor-1 and C-Reactive Protein Are Markers of Thrombolytic Efficacy in Acute Myocardial Infarction

1992 ◽  
Vol 68 (06) ◽  
pp. 678-682 ◽  
Author(s):  
F Andreotti ◽  
D R Hackett ◽  
A W Haider ◽  
M C Roncaglioni ◽  
G J Davies ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor

SummaryPlasma von Willebrand factor, plasminogen activator inhibitor activity and C-reactive protein were assessed as markers of coronary recanalisation in 30 patients with acute myocardial infarction receiving tissue-type plasminogen activator (t-PA). Blood samples were taken before t-PA (time 0), 4-hourly for 24 h and daily up to 72 h. A continuous electrocardiogram was recorded in the first 24 h. Coronary arteriography was performed 90 min and 24 h after the start of t-PA. Patients with a patent infarct artery (n = 17), compared to those with occluded artery (n = 13), showed a fall in von Willebrand factor from 0 to 24 h (p = 0.001), a greater fall in plasminogen activator inhibitor from 24 to 48 h (p = 0.04) and a fall in C-reactive protein from 48 to 72 h (p = 0.002). The accuracy of these indices compared favourably with time to peak plasma MB creatine kinase and ≥ 50% resolution of maximal ST-deviation on the electrocardiogram.Thus, changes in plasma von Willebrand factor, plasminogen activator inhibitor and C-reactive protein during the first 3 days of myocardial infarction are indicative of thrombolytic efficacy. Their concordant behaviour may reflect a common regulatory mechanism.

von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

1995 ◽  
Vol 74 (02) ◽  
pp. 626-630 ◽  
Author(s):  
A D Blann ◽  
M Dobrotova ◽  
P Kubisz ◽  
C N McCollum
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
Tissue Plasminogen ◽  
Soluble P ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor ◽  
Pai 1

SummaryTissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.

Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age

1986 ◽  
Vol 55 (03) ◽  
pp. 330-332 ◽  
Author(s):  
M F Aillaud ◽  
F Pignol ◽  
M C Alessi ◽  
J R Harle ◽  
M Escande ◽  
...  
Keyword(s):  
Plasma Concentration ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Sedimentation Rate ◽  
Acute Phase Proteins ◽  
Plasminogen Activator Inhibitor ◽  
Erythrocyte Sedimentation ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor

SummaryElderly patients have previously been shown to have an increased plasma concentration of tissue plasminogen activator (t-PA) antigen (t-PAAg). Since the concentration of t-PA Ag dependson both free t-PA and t-PA complexed with inhibitors, mainly plasminogen activator inhibitor (PA inhibitor), we have investigated the relationship between the plasma concentration of PA inhibitor and age in 20 elderly and 20 young individuals. Elderly individuals showed a slight increase in PA inhibitor, in parallel with increase on others, acute-phase proteins, fibrinogen, von Willebrand factor, factor VIII :C, and the erythrocyte sedimentation rate. The increase i PA inhibitor as well as other acute-phase proteins in the elderly may be significant in relation to the increased incidence of thrombotic disease.

scholarly journals Effects of Losartan on Fibrinolytic Parameters and von Willebrand Factor in Chinese Subjects with Hypertension: A Comparative Study versus Atenolol

2009 ◽  
Vol 37 (3) ◽  
pp. 595-600 ◽  
Author(s):  
J Liu ◽  
N-L Sun ◽  
J Yang ◽  
J-H Huang
Keyword(s):  
Blood Pressure ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Fibrinolytic Parameters ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Chinese Subjects ◽  
Pai 1

To compare the effects of losartan and atenolol on plasma fibrinolytic parameters and von Willebrand factor (vWF), Chinese subjects with mild-to-moderate hypertension were randomized to receive losartan (50 mg/day; n = 30) or atenolol (50 mg/day; n = 30) for 8 weeks. If target blood pressure (< 140/90 mmHg) was not achieved at week 4, hydrochlorothiazide (12.5 mg/day) was also administered. Plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and vWF were determined at baseline and after treatment. Between-group baseline characteristics and blood pressure decrease were comparable. Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Atenolol significantly increased plasma tPA, but PAI-1, vWF and PAI-1/tPA ratio were unchanged. In conclusion, losartan, but not atenolol improved the fibrinolytic system and reduced plasma vWF levels in Chinese hypertensives.

Sign in / Sign up

Export Citation Format

Share Document